Clearmind enrolls first alcohol-use-disorder patients in CMND-100 trial
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
12:03:22 PM UTC
SquawkNews
Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. NASDAQ:CMND (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders includ…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.